Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1
Skye Bioscience Says Cohort Review Committee Unanimously Approves Opening Second Cohort Of CBeyond Part C Expansion Study
UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
Skye Bioscience Q1 EPS $(0.32) Misses $(0.31) Estimate
Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit
Skye Bioscience To Highlight Its Approach To Enhancing GLP‑1 Efficacy While Reducing Safety Risks At GLP-1-Based Therapeutics Summit In Boston
Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development
Skye Bioscience Treats First Patient In Part C Expansion Study Of CBeyond Phase 2a Trial To Characterize Safety And PK At Exposures To Challenge Peripheral Restriction Of Nimacimab Through IV Administration Over 16 Weeks Of Treatment
Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pioneering Advances in Obesity ...
Skye Bioscience shares are trading lower after the company reported a Q4 EPS miss.
Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Skye Bioscience, Inc. 2025 Q4 - Results - Earnings Call Presentation
Skye Bioscience Q4 EPS $(0.36) Misses $(0.30) Estimate
A Peek at Skye Bioscience's Future Earnings
Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026
Skye Bioscience CFO Kaitlyn Arsenault To Step Down, Effective Immediately; CEO Punit Dhillon Appointed Principal Accounting Officer
Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.